Stock VTGN VISTAGEN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Vistagen Therapeutics, Inc.

Equities

VTGN

US92840H4002

Delayed Nasdaq
Other stock markets
 12:43:07 28/06/2024 am IST 		5-day change 1st Jan Change
3.48 USD +7.08% Intraday chart for Vistagen Therapeutics, Inc. +8.07% -32.30%
11/06 Transcript : Vistagen Therapeutics, Inc., Q4 2024 Earnings Call, Jun 11, 2024
11/06 Vistagen Therapeutics, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024 CI

Evolution of the average Target Price on Vistagen Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

afe88af3780e39901bdf66c06bb.um2NNq10YaQUn8wkarK8C360OLjECPGwH4ztoBheNeA.y17eVe4xBct-yrYSJvHbYSzBa9KsRZTpWLi_8UsLXJnfG_lC9RUr-1bxuw~a941a10a745d037b94f0c76f317affbb

Analyst Recommendations on Vistagen Therapeutics, Inc.

Jefferies Upgrades VistaGen Therapeutics to Buy From Hold, Raises Price Target to $15 From $6 MT
Stifel Starts VistaGen Therapeutics With Buy Rating, $12 Price Target MT
Maxim Cuts Price Target on VistaGen Therapeutics to $12 From $30, Maintains Buy Rating MT
Maxim Downgrades VistaGen Therapeutics to Hold From Buy MT
Jefferies Downgrades VistaGen Therapeutics to Hold from Buy, Adjusts Price Target to $0.20 from $8 MT
William Blair Downgrades VistaGen Therapeutics to Market Perform From Outperform MT
VISTAGEN THERAPEUTICS : Baird Starts VistaGen Therapeutics at Outperform With $9 Price Target MT
VISTAGEN THERAPEUTICS : Jefferies Starts VistaGen Therapeutics at Buy with $6 Price Target MT
VISTAGEN THERAPEUTICS : William Blair Upgrades VistaGen Therapeutics to Outperform From Market Perform MT
VISTAGEN THERAPEUTICS : Maxim Adjusts Price Target on VistaGen Therapeutics to $5 From $3, Reiterates Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.25 USD
Average target price
14 USD
Spread / Average Target
+330.77%
High Price Target
17 USD
Spread / Highest target
+423.08%
Low Price Target
12 USD
Spread / Lowest Target
+269.23%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Vistagen Therapeutics, Inc.

Jefferies & Co.
Stifel Nicolaus
Maxim
William Blair & Co.
Baird

Ratings for Vistagen Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. VTGN Stock
  4. Consensus Vistagen Therapeutics, Inc.